Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

testosterone 1.62% gel

Phase 2

SSeattle Institute for Biomedical and Clinical Research

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hypogonadism, MaleActive, not recruiting

Hypogonadism, MalePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hypogonadism, Male

NCT04301765

Clinical

Trials by Indication[1]

Hypogonadism, Male1 trial

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

Active, not recruiting·SSeattle Institute for Biomedical and Clinical Research·Phase 2·NCT04301765·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for testosterone 1.62% gel. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for testosterone 1.62% gel. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Seattle Institute for Biomedical and Clinical Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSeattle Institute for Biomedical and Clinical Research

Related News